DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years

Information source: Universitštsklinikum Hamburg-Eppendorf
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Acute Myeloid Leukemia

Intervention: Sunitinib (Drug)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: Universitštsklinikum Hamburg-Eppendorf

Official(s) and/or principal investigator(s):
Walter Fiedler, Principal Investigator, Affiliation: Universitätsklinikum Hamburg-Eppendorf


In this study safety and tolerability of two dose levels of SU 11248 (sutent) with standard chemotherapy in patients with FLT3 mutated AML over 60 years will be evaluated.

Clinical Details

Official title: Phase I/II Clinical Study of SU11248 (Sutent) Combined With Standard Chemotherapy With Cytosine Arabinoside and Daunorubicin in Patients With FLT3 Mutated AML Over 60 Years of Age

Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Definition of a recommended Phase III dose and determination CTC version 3.0 grade 3-5 non-hematological toxicities of SU11248 in combination with standard induction and consolidation chemotherapy

Secondary outcome:

Overall safety profile of SU11248 characterized by type, frequency, severity (graded using NCI CTCAE Version 3.0), timing and relatedness of adverse events (AEs) and laboratory

Objective tumor response, as defined using the revised recommendations of the International Working Group for diagnosis, standardization of response criteria in Acute Myeloid Leukemia for AML


Minimum age: 60 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Patients with primary or secondary acute myeloid leukemia (any FAB type, except M3).

- No prior systemic chemotherapy for AML except hydroxyurea. Cytoreductive therapy with

hydroxyurea is recommended if WBC is > 50. 000/¬Ķl, but should cease at least one day prior to starting study medication

- Patient age equal or of greater than 60 years

- Patients must have FLT3 mutated AML, either ITD or kinase domain mutations

- ECOG Performance score 3 or less (Karnofsky Performance Score >40%).

- Life expectancy more than four weeks.

- Adequate hepatic and renal function, as defined by serum transaminases <2. 5x ULN,

bilirubin <1. 5x ULN. Creatinine <1. 5x ULN.

- Patients must provide written informed consent to participate in the trial.

- Normal heart function on cardiac ultrasound

- Prothrombin time (PT) and partial thromboplastin time (PTT) <=1. 5 x ULN

- Serum albumin >=3. 0 g/dl

- Serum amylase and lipase <=1. 0 x ULN

- Willingness and ability to comply with scheduled visits, treatment plans, laboratory

tests, and other study procedures. Exclusion Criteria: The presence of any of the following will exclude a subject from study enrollment:

- Treatment with any investigational agent within four weeks.

- Known HIV infection

- Presence of any medical or psychiatric condition which may limit full compliance with

the study, including but not limited to:

- Presence of CNS leukaemia

- Unresolved toxicity from previous anti-cancer therapy or incomplete recovery from


- Any of the following within the 12 months prior to study drug administration:

myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other thromboembolic event.

- Current treatment with therapeutic doses of anticoagulant (low dose Coumadin up to 2

mg PO daily for deep vein thrombosis prophylaxis is allowed).

- Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal

medical therapy).

- Pre existing thyroid abnormality of thyroid function that cannot be maintained in the

normal range with medication.

- Ongoing cardiac dysrhythmias of NCI CTCAE Grade >=2, atrial fibrillation of any

Grade, or prolongation of the QTc interval to >450 msec for males or >470 msec for females.

- Other severe acute or chronic medical or psychiatric condition, or laboratory

abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.

Locations and Contacts

Prof. Dr. med. Walter Fiedler, Hamburg 20246, Germany

PD Dr. med. J√ľrgen Krauter, Hannover 30625, Germany

Dr. Katharina G√∂tze, M√ľnchen 81675, Germany

Prof. Dr. Helmut R. Salih, T√ľbingen 72076, Germany

Dr. Richard Schlenk, Ulm 89081, Germany

Additional Information

Starting date: August 2008
Last updated: September 20, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017